SPAC Presentation
In-House R&D Capabilities Driving Attractive Growth Opportunities
Clear Avenues for Growth Given a Robust Pipeline and a High Product Renewal Rate
High Product Renewal Rate
3-4%
R&D Annual Investment
(% of Gross Revenues)
14%
2018
15+
Average years of
experience
19%
Strong New Development Capacity
600+
Products developed
in softgels
2019
22%
2020
10+
Experienced personnel
in MKTG & NBD
50+
Softgels products launched
annually worldwide
Product Renewal Ratio¹ (%)
25%
Expected
270+
Skilled personnel in
R&D and Innovation
100+
Assertive personnel
in Regulatory Affairs
Source: Procaps
Note: (1) Gross revenues of new products (products launched within the last 36 months) / total gross revenues
B2B
High Share of Sales Linked to Procaps' Own Technologies
Share of Sales by Channel (%), 2020
Robust Pipeline
Category
Patents
Trademarks
86%
Drug
Registration
→ DO
PROCAPS
B2C
52%
Granted
PROCAPS
34
5,335
3,472
51
Pending Approval
62%
372
GROUP
1,632
****
19View entire presentation